The North America life science industry was valued at USD 39.70 billion in 2025 and is projected to reach approximately USD 124.18 billion by 2035, increasing from USD 44.49 billion in 2026 at a CAGR of 12.08% from 2026 to 2035.
The industry is being propelled by rising biotechnology and biopharmaceutical investments, increasing demand for precision medicine, expanding clinical trials, and rapid adoption of AI, genomics, automation, and advanced therapeutic technologies.
Key Trends
- U.S. accounted for approximately 88% of North America’s life science revenue in 2025.
- Instruments held the largest product-type share at approximately 50%.
- Software & services are expected to experience the fastest growth.
- Genomics represented approximately 45% of the technology segment.
- AI and digital platforms are emerging as the fastest-growing technology area.
- Drug discovery and development accounted for approximately 42% of applications.
- Personalized medicine is expected to register the fastest application growth.
- Pharmaceutical and biotechnology companies represented approximately 44% of end-user demand.
- Hospitals and clinical research laboratories are expected to expand rapidly.
What Is Driving the North America Life Science Industry?
Strong research and development activity remains a fundamental growth engine across the region. Increasing chronic diseases, cancer cases, rare diseases, and demand for advanced therapies are encouraging pharmaceutical and biotechnology companies to invest in drug discovery, genomics, diagnostics, and personalized treatments.
North America also benefits from an established ecosystem of pharmaceutical companies, biotechnology startups, academic institutions, CROs, CDMOs, and advanced research laboratories. Government funding and private investment are further supporting innovation in cell and gene therapy, gene editing, next-generation sequencing, and precision medicine.
AI Is Reshaping Life Science Research
Artificial intelligence is becoming increasingly important across drug discovery, clinical trials, diagnostics, genomics, and personalized medicine.
AI-powered platforms can analyze large-scale biological and clinical datasets, identify potential drug targets, support biomarker discovery, optimize clinical trial processes, and help researchers develop more targeted therapies.
The emergence of AI-driven virtual cell models, multi-omics analytics, laboratory automation, and digital research platforms could significantly shorten development timelines while improving research efficiency.
Segment Highlights
Instruments remained the largest product category in 2025, supported by increasing R&D activity, clinical research, and demand for advanced laboratory equipment.
Genomics led the technology segment with approximately 45%, driven by growing demand for personalized medicine, cancer research, mutation detection, biomarker identification, and targeted therapies.
Drug discovery and development accounted for approximately 42% of applications. Increasing pharmaceutical R&D, chronic disease prevalence, and adoption of AI and genomics are strengthening this segment.
Meanwhile, personalized medicine is expected to experience rapid expansion as healthcare providers and researchers increasingly focus on targeted treatments for cancer, rare diseases, and complex conditions.
U.S. Outlook
The United States held approximately 88% of the North American life science industry in 2025.
Its leadership is supported by substantial R&D spending, a strong biotechnology startup ecosystem, advanced research infrastructure, leading pharmaceutical companies, and rapid adoption of AI and genomics.
Investment is also expanding advanced manufacturing capabilities. For example, a new biopharmaceutical manufacturing facility by FUJIFILM Biotechnologies in Holly Springs, North Carolina, represents a major investment in the region’s biopharmaceutical infrastructure.
Canada Outlook
Canada is strengthening its position through biotechnology research, genomics, precision medicine, and advanced therapeutic development. Growing investments in life science startups, clinical research, and biopharmaceutical manufacturing are creating additional opportunities across the country.
Future Outlook
The North American life science industry is entering a period of rapid technological transformation. AI-driven drug discovery, genomics, precision medicine, cell and gene therapies, synthetic biology, laboratory automation, and regenerative medicine are expected to remain major areas of innovation.
At the same time, companies will need to address high R&D costs, regulatory complexity, specialized talent shortages, supply-chain resilience, cybersecurity, and intellectual-property protection.
Download Customized Sample: https://www.towardshealthcare.com/download-sample/6278
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium